Streetbeat News

Products Services

KITT

Nauticus Robotics, Inc. (NASDAQ:KITT) shares fell 15.9% after reporting Q2 losses of $2.75 per share on revenue of $501,710, a 55.53% decrease from last year. The company is upgrading its deepwater electronics and expects to expand revenue opportunities with two working vehicles. CEO John Gibson highlighted ongoing support from lenders and progress in a program for a major offshore producer in Brazil.

Portfolio Pulse from Erica Kollmann

August 14, 2024 | 6:47 pm

LLY

NVO

Eli Lilly (NYSE:LLY) has issued cease-and-desist letters to U.S. healthcare providers to stop promoting compounded versions of its weight-loss drugs, Mounjaro and Zepbound, as the supply of these medications has improved. The FDA is evaluating whether the supply meets the criteria for resolving the shortage. Novo Nordisk (NYSE:NVO) is also mentioned as having faced similar shortages. LLY stock is up 2.46%.

Portfolio Pulse from Vandana Singh

August 14, 2024 | 6:35 pm

SILO

Silo Pharma has entered into an agreement with Sever Pharma Solutions to scale up production and continue testing of its SP-26 dissolvable ketamine-based implant, which targets chronic pain and fibromyalgia.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:30 pm

FTXL

GGME

QCOM

TSM

Qualcomm (QCOM) is expected to benefit from its edge AI positioning in smartphones and PCs, as well as its expanding presence in the auto sector. KeyBanc Capital Markets analyst John Vinh maintained an Overweight rating and a $225 price target for QCOM. Despite strong Q3 results, QCOM shares are trading lower due to potential headwinds, including the revoking of its license to sell to Huawei. Investors can gain exposure to QCOM through ETFs like Invesco Next Gen Media And Gaming ETF (GGME) and First Trust Nasdaq Semiconductor ETF (FTXL).

Portfolio Pulse from Lekha Gupta

August 14, 2024 | 6:26 pm

BEAM

KRRO

WVE

William Blair initiated coverage on Korro Bio Inc. (NASDAQ:KRRO) with an Outperform rating, highlighting its proprietary OPERA platform for RNA editing. The analyst also noted the upcoming clinical data release from Wave Life Sciences Ltd (NASDAQ:WVE) and mentioned Beam Therapeutics Inc (NASDAQ:BEAM) as a validating but differentiable competitor.

Portfolio Pulse from Vandana Singh

August 14, 2024 | 6:21 pm

KAYS

Kaya Holdings, Inc. (OTCQB:KAYS) criticizes the FDA's decision to reject MDMA for PTSD treatment and advocates for psilocybin as an alternative. KAYS operates The Sacred Mushroom, a psilocybin treatment facility in Oregon, and invites those seeking psilocybin therapy. CEO Craig Frank expressed disappointment with the FDA's decision and highlighted the potential benefits of psilocybin therapy, supported by recent studies.

Portfolio Pulse from Juan Spínelli

August 14, 2024 | 6:13 pm

AAPL

Apple is advancing its efforts in developing tabletop robots, a project led by a former car chief. This move signifies Apple's continued diversification and innovation in new technology sectors.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:09 pm

DNLI

Denali Therapeutics (NASDAQ:DNLI) announced the publication of nonclinical data in 'Science Translational Medicine' demonstrating the potential of its Oligonucleotide Transport Vehicle (OTV) platform to achieve broad biodistribution of antisense oligonucleotides (ASOs) in the CNS and skeletal and cardiac muscle following IV administration. This breakthrough could address the challenge of delivering ASOs across the blood-brain barrier (BBB) for the treatment of neurological disorders.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:02 pm

SBIG

SpringBig Holdings, Inc. (OTCQX:SBIG) reported a narrowed net loss for Q2 2024, with revenue totaling $6.6 million, an 8.3% YoY decline but a 2% QoQ increase. The company highlighted the traction of new offerings and reduced operating expenses by 36% YoY. Adjusted EBITDA turned positive at $0.3 million.

Portfolio Pulse from Jelena Martinovic

August 14, 2024 | 5:57 pm

ABT

EBS

MRNA

SIGA

The World Health Organization (WHO) announced that an expert committee will propose the adoption of Mpox vaccines under Emergency Use Listing around mid-September.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:55 pm